# Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

> **NCT05141682** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jonathan Brammer** · enrollment: 11 (actual)

## Conditions studied

- T-Cell Large Granular Lymphocyte Leukemia

## Interventions

- **DRUG:** Oral Azacitidine

## Key facts

- **NCT ID:** NCT05141682
- **Lead sponsor:** Jonathan Brammer
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-29
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-30
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141682, "Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05141682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*